Why is Natco Pharma falling/rising?

As of 05-Aug, Natco Pharma Ltd. is experiencing a decline in its stock price, currently at 932.85, which reflects a decrease of 2.45 or 0.26%. The stock has underperformed in the short term, with a 1-week return of -2.76% and a 1-month return of -6.56%. Today's performance indicates that it has outperformed its sector by 0.69%, although it is trading below its 5-day, 20-day, and 200-day moving averages, while remaining above the 50-day and 100-day averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 53.87% compared to the 5-day average. Despite these challenges, the company maintains a high management efficiency with a return on equity (ROE) of 15.57%, a low debt-to-equity ratio, and healthy long-term growth in operating profit.
In the broader market context, Natco Pharma's performance has been notably weaker than the benchmark Sensex, which has seen a positive return of 3.29% year-to-date compared to the stock's decline of 32.74%. This disparity highlights the stock's struggles in a generally favorable market environment. While the stock has a very attractive valuation with a PEG ratio of 0.3 and high institutional holdings at 21.33%, the overall negative returns over the past year, combined with a decline in trading volume, suggest that investor sentiment remains cautious. The stock's recent performance reflects a complex interplay of strong fundamentals and market pressures that have led to its current downward trajectory.